• NEC will present Phase I/II results for oral cancer therapy NECVAX-NEO1 at ESMO in Madrid on October 23, 2026.
• The trial tested the individualized therapy with pembrolizumab and chemotherapy before surgery in patients with early-stage triple-negative breast cancer.
• Treatment was generally well tolerated, with immune responses detected in all patients; some had no remaining cancer detected at surgery.
• The trial is expanding to 28 patients, including U.S. participants following regulatory clearance, with the second cohort receiving a higher dose.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NEC Corporation published the original content used to generate this news brief on October 22, 2026, and is solely responsible for the information contained therein.